SARSTer jest retrospektywnym, nieinterwencyjnym programem badawczym finansowanym ze środków Polskiego Towarzystwa Epidemiologów i Lekarzy Chorób Zakaźnych oraz Agencji Badań Medycznych, we współpracy z firmą Tiba. Celem badania jest ocena skuteczności i bezpieczeństwa różnych opcji terapii COVID-19 stosowanych w Polsce u chorych leczonych począwszy od 1 marca 2020. Szczególny nacisk został położony na terapie zalecane w rekomendacjach PTEiLChZ, co pozowoli na ich doskonalenie. Uzyskane dane będą analizowane, w zależności od wielu parametrów wyjściowych i z uwzględnieniem różnych punktów końcowych oceniających skuteczność terapii. Badanie jest realizowane na platformie internetowej wykorzystywanej uprzednio w projektach EpiTer-2 i EpiGeneS we współpracy z firmę Tiba. W projekcie uczestniczy 30 polskich ośrodków leczących zakażenia SARS-CoV-2, w tym 10 pediatrycznych. Podstawowym kryterium włączenia jest rozpoznanie COVID-19. Dodatkowe kryteria będą zależne od cząstkowych analiz, których celem będzie opracowanie danych do publikacji. Pozyskane dzięki SARSTer informacje pozwolą na zoptymalizowanie postępowania terapeutycznego w COVID-19.
Publikacje:
- Tocilizumab for patients with severe COVID-19: a retrospective, multi-center study
- Remdesivir based therapy improve significantly recovery of patients with COVID-19 in the SARSTer multicentre, real world experience study.
- Convalescent Plasma Transfusion for the Treatment of COVID-19—Experience from Poland: A Multicenter Study
- Administration of tocilizumab to patients with high concentrations of IL-6 in the course of COVID-19 is associated with a better prognosis
- Impact of Kidney Failure on the Severity of COVID-19
- Clinical Characteristics of Hospitalized COVID-19 Patients Who Received at Least One Dose of COVID-19 Vaccine
- Effectiveness of Tocilizumab with and without Dexamethasone in Patients with Severe COVID-19: A Retrospective Study
- Pneumonia, gastrointestinal symptoms, comorbidities, and coinfections as factors related to a lengthier hospital stay in children with COVID-19—analysis of a paediatric part of Polish register SARSTer.
- Clinical and Epidemiological Characteristics of 1283 Pediatric Patients with Coronavirus Disease 2019 during the First andSecond Waves of the Pandemic—Results of the Pediatric Part of a Multicenter Polish Register SARSTer
- Effect of COVID-19 on Anti-S Antibody Response in Healthcare Workers Six Months Post-Vaccination
- Demographic and clinical overview of hospitalized COVID-19 patients during the first 17 months of the pandemic in Poland
- Does Hospitalization Change the Perception of COVID-19 Vaccines among Unvaccinated Patients?
- Severe Breakthrough COVID-19 Cases during Six Months of Delta Variant (B.1.617.2) Domination in Poland
- Inflammatory and thrombotic parameters associated with the COVID-19 course in Poland (SARSTer study)
- The association of airborne particulate matter and benzo[a]pyrene with the clinical course of COVID-19 in patients hospitalized in Poland
- Air pollution might affect the clinical course of COVID-19 in pediatric patients
- Real‑world experience with molnupiravir during the period of SARS‑CoV‑2 Omicron variant dominance
- Remdesivir decreases mortality in COVID-19 patients with active malignancy
- The course of COVID-19 in patients with systemic autoimmune rheumatic diseases
- Variability in the Clinical Course of COVID-19 in a Retrospective Analysis of a Large Real-World Database
- Retrospective Analysis of the Effectiveness of Remdesivir in COVID-19 Treatment during Periods Dominated by Delta and Omicron SARS-CoV-2 Variants in Clinical Settings
- Clinical Course and Severity of COVID-19 in 940 Infants with and without Comorbidities Hospitalized in 2020 and 2021: The Results of the National Multicenter Database SARSTer-PED
- Differences between the course of SARS‑CoV‑2 infections in the periods of the Delta and Omicron variant dominance in Poland
- Short‐term exposure to ambient air pollution and COVID‐19 severity during SARS‐CoV‐2 Delta and Omicron waves: A multicenter study
- Change in the Clinical Picture of Hospitalized Patients with COVID-19 between the Early and Late Period of Dominance of the Omicron SARS-CoV-2 Variant
- Differences in Clinical Presentation of COVID-19 in Children Hospitalized During Domination of Early (BA.1, BA.2) and Late (BA.5, BA.2.75, BQ.1 and XBB.1.5) SARS-CoV-2 Omicron Subvariants
- Association between Liver Damage and Disease Progression Markers with Mortality Risk and Mechanical Ventilation in Hospitalized COVID-19 Patients: A Nationwide Retrospective SARSTer Study